Clinical Trials

Tennessee Retina is an active participant in many national research trials. The efforts of our physicians and patients have led to the approval of many treatments now considered to be the standard of care, and our continuing involvement in clinical research offers access to new and potentially superior treatments to patients with sight-threatening conditions.

Please call 615-983-6000 for more information and participation criteria in our active clinical trials.

Current Trials

Age Related Macular Degeneration – AMD

Ohr Study - Phase 2 study of the efficacy and safety of an investigational drug administered topically twice daily in subjects with neovascular age-related macular degeneration. (Active, Currently Recruiting)

Pfizer Study – A Phase 2 study of efficacy, safety, pharmacokinetics and pharmacodynamics of an investigational drug administered intravenously in subjects with geographic atrophy secondary to age-related macular degeneration. (Open Enrollment Status Pending)

ROLL Study – A Phase 4 IST using On-label tReatment with intravitreal aflibercept injectiOn for patients with persistent pigment epitheliaL detachments in neovascuLar AMD (ROLL). (Active, enrollment closed)

DO-DO Study – An IST that compares dosing intervals using standard dose, DOuble DOse as well as quadruple dose of ranibizumab (Lucentis®) injections for the treatment of wet AMD. (Active, enrollment closed)

Genentech/Roche Mahalo Study – A Phase Ib/II controlled study of safety, tolerability and evidence of activity of Anti-Factor D intravitreal injections administered monthly or every other month to patients with geographic atrophy (GA). (Active, enrollment closed)

ForeseeHome Device Study/NotalVision – A device study used to assess the accuracy of the ForeseeHome to detect reactivation of CNV following the successful treatment with Anti-VEGF. (Active, enrollment closed)

Retinal Vein Occlusion

Regeneron Vibrant Study – A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection-IAI) in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion. (Active, Currently Recruiting)

Diabetic Retinopathy

Regeneron Vista study – Evaluating 2.0mg VEGF – Trap Eye on 2 treatment intervals versus laser therapy in patients with diabetic macular edema. This is a 3 year study for Regeneron. (Active, enrollment closed)

Previous Clinical Trials

For Previous Trials click here

Our study patients are very important to us, and we provide them with exceptional care and attention. Please contact your current eyecare provider to see if you may qualify for one of our studies, or contact one of our Clinical Trial staff members listed below with any questions at (615) 983-6000.

 
Sarah Hines, COA - Clinical Research Coordinator
Pam Keesee - Clinical Research Assistant